Drug discovery requires the combination of medicinal chemistry and biology. In this article Chris Lipinski, the medicinal chemist, describes the chemical origins at Pfizer of Tolimidone¹ the starting point for the repurposed MLR-1023². Andrew Reaume, the biologist, describes his motivation to develop a high quality (i.e. in vivo model) phenotypic screening platform as an ideal drug repositioning platform.

中文翻译：

---

高通量药物利用的体内表型筛选：具有临床概念验证的新型胰岛素增敏剂和新型Lyn激酶激活剂MLR-1023的发现

药物发现需要药物化学和生物学的结合。在本文中，药用化学家Chris Lipinski描述了Tolimidone ¹辉瑞公司的化学起源，这是重新使用的MLR-1023 ²的起点。生物学家安德鲁·雷姆（Andrew Reaume）描述了他开发高质量（即体内模型）表型筛选平台作为理想药物重新定位平台的动机。